Dr. Stephen J. Pollard, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- University of Louisville School of Medicine (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 524
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: University of Louisville School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
KY license 18615 · IN license 01026960A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Hardin Elizabethtown, KY
Medical groups
- Psf PLLC (98 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 524
- Services billed
- 42,051
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 7,880 | 300 |
| Professional service for multiple injections of allergen | 5,778 | 297 |
| Test for allergy using allergenic extract | 4,812 | 62 |
| Test for allergy using allergenic extract injected into skin | 1,972 | 57 |
| Administration and interpretation of patient-focused health risk assessment | 328 | 229 |
| Established patient office or other outpatient visit, 20-29 minutes | 257 | 192 |
| Test to measure the level of nitric oxide gas | 230 | 159 |
| Test to measure expiratory airflow and volume | 197 | 140 |
| Injection of drug or substance under skin or into muscle | 158 | 19 |
| Professional service for single injection of allergen | 154 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Louisville, KY | 742 |
| Fluticasone Propionate Other prescribers in Louisville, KY | 200 |
| Azelastine Hcl Other prescribers in Louisville, KY | 167 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Louisville, KY | 147 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Louisville, KY | 144 |
| Prednisone Other prescribers in Louisville, KY | 121 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Louisville, KY | 115 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Louisville, KY | 107 |
| Epinephrine Other prescribers in Louisville, KY | 99 |
| Famotidine Other prescribers in Louisville, KY | 81 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 57 payments worth $26,450 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $9,561 |
|---|---|
| Genzyme Corporation | $8,302 |
| GlaxoSmithKline, LLC. | $5,710 |
| Incyte Corporation | $2,232 |
| AstraZeneca Pharmaceuticals LP | $286 |
| Novartis Pharmaceuticals Corporation | $104 |
| Amgen Inc. | $51.51 |
| Biocryst US Sales Co., LLC | $48.86 |
| Compensation for services other than consulting (speaking, faculty) | $21,884 |
|---|---|
| Consulting Fee | $2,180 |
| Food and Beverage | $1,442 |
| Travel and Lodging | $910 |
| Education | $34.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT; DUPIXENT · Immunology | $7,340 |
| Regeneron Healthcare Solutions, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,845 |
| Regeneron Healthcare Solutions, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,621 |
| GlaxoSmithKline, LLC. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) NUCALA · IMMUNOLOGY | $2,600 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) NUCALA · IMMUNOLOGY | $2,600 |
| Incyte Corporation Nov 25, 2025 | Consulting Fee | $2,180 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,829 |
| Regeneron Healthcare Solutions, Inc. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,049 |
| Genzyme Corporation Oct 16, 2025 | Travel and Lodging DUPIXENT; DUPIXENT · Immunology · travel to Bowling Green, KY · in-kind | $810 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Travel and Lodging NUCALA · IMMUNOLOGY · travel to Lexington, KY | $100 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Nov 25, 2025 | Consulting Fee | $2,180 |
| Genzyme Corporation Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT; DUPIXENT · Immunology | $7,340 |
| Genzyme Corporation Oct 16, 2025 | Travel and Lodging DUPIXENT; DUPIXENT · Immunology · travel to Bowling Green, KY · in-kind | $810 |
| Amgen Inc. Jul 25, 2025 | Education in-kind | $34.00 |
| Regeneron Healthcare Solutions, Inc. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,049 |
| Regeneron Healthcare Solutions, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,845 |
| Regeneron Healthcare Solutions, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,621 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,829 |
| GlaxoSmithKline, LLC. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) NUCALA · IMMUNOLOGY | $2,600 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Travel and Lodging NUCALA · IMMUNOLOGY · travel to Lexington, KY | $100 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) NUCALA · IMMUNOLOGY | $2,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $26,642 in research payments for these studies, mostly to the institutions running them.
- A phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma
AstraZeneca Pharmaceuticals LP - A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - Registry of Asthma Patients Initiating DUPIXENT®
Regeneron Pharmaceuticals, Inc. · Completed · NCT04287621
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.